Why Is Vimpat a Controlled Substance: DEA & Abuse Risk

Vimpat (lacosamide) is classified as a Schedule V controlled substance by the U.S. Drug Enforcement Administration, the lowest tier of scheduling under the Controlled Substances Act. That placement reflects a judgment call: clinical studies detected some abuse-related subjective effects at very high doses, but those effects were modest compared to well-known drugs of abuse and came packaged with enough unpleasant side effects to discourage recreational use. The story behind the scheduling reveals a tension between regulatory caution and the practical consequences for people who need the drug every day to control seizures.

How Lacosamide Ended Up on the DEA’s Schedule

When the FDA approved lacosamide in 2008 for add-on treatment of partial-onset seizures in adults, the DEA conducted its own review to decide whether the drug needed scheduling. In 2009, the agency issued a final rule placing lacosamide into Schedule V of the Controlled Substances Act.¹ That designation covers any material, compound, mixture, or preparation containing any quantity of lacosamide.

Schedule V is the least restrictive controlled-substance category. To put it in familiar terms, it sits alongside things like certain cough preparations containing small amounts of codeine. Drugs in Schedule V are considered to have a low potential for abuse relative to Schedule IV substances (which include drugs like benzodiazepines and sleep aids). Still, the scheduling label carries real regulatory weight: it means prescriptions are tracked, refills are limited or require additional verification, and pharmacies must handle the drug under controlled-substance protocols.

The DEA’s decision was based partly on the drug’s chemical structure, partly on its pharmacological profile, and largely on the results of formal human abuse-potential studies conducted as part of the approval process. These studies are now standard for newer antiseizure drugs, several of which have also ended up scheduled.²

What the Abuse-Potential Studies Actually Found

The pivotal study behind the scheduling decision was a randomized, double-blind, crossover trial in healthy recreational drug users, the population the FDA considers most relevant for detecting whether a drug produces the kind of high that people might seek out. Participants received lacosamide at 200 mg (a normal therapeutic dose) and 800 mg (four times the typical dose), and these were compared against placebo and two doses of alprazolam (a well-known benzodiazepine).³

At the 200 mg dose, lacosamide looked essentially like a sugar pill. Mean subjective effects were statistically similar to placebo and significantly lower than alprazolam on most measures. In other words, at the dose people actually take for epilepsy, there was no detectable “buzz.”

The 800 mg dose was more complicated. It did produce brief, statistically significant positive subjective effects compared with placebo, the kind of transient euphoria that gets flagged in abuse-potential assessments. But those positive effects came with persistent unpleasant ones: nausea and dysphoria scores were significantly higher than with any other treatment in the study. This is the pharmacological equivalent of a drink that tastes good for a second and then makes you feel sick.

On the measures that matter most for predicting real-world abuse, the 800 mg dose was underwhelming. The “Overall Drug Liking” and “Take Drug Again” scores for 800 mg lacosamide were not significantly different from placebo and were significantly lower than both alprazolam doses. Even the “at this moment” Drug Liking score for lacosamide 800 mg was lower than for the higher alprazolam dose, though it overlapped with the lower alprazolam dose. The study authors concluded that lacosamide has “detectable abuse-related subjective effects, but a relatively low potential for abuse compared with alprazolam.”³

Preclinical Data Told a Different Story

Before the human abuse-potential study was conducted, animal studies had been more reassuring. In safety pharmacology and toxicology research involving mice, rats, rabbits, and dogs, lacosamide was well tolerated, and researchers found no indication of abuse liability.⁴ Animals did not self-administer the drug or prefer it over placebo in the paradigms typically used to screen for abuse potential.

This disconnect between clean animal data and the detectable-but-modest signals in human recreational users is not unusual in drug scheduling. Animal models are good at catching drugs with strong reinforcing effects but can miss subtler subjective experiences that show up when you ask human beings whether they liked how a drug made them feel. The DEA tends to err on the side of caution: if the human study shows any signal at all, even a weak one dampened by unpleasant side effects, the drug gets some level of scheduling.

What Makes Lacosamide Different Pharmacologically

Lacosamide works differently from older seizure drugs, and that difference is relevant to understanding both its therapeutic value and its controlled-substance status. Classic sodium channel blockers like carbamazepine and phenytoin work by binding tightly to what is called the fast-inactivated state of sodium channels, essentially grabbing onto the channel quickly after it fires and preventing it from firing again too soon. Lacosamide, by contrast, enhances a slower process. It shifts the voltage dependence of slow inactivation toward more negative potentials, making it harder for overactive neurons to keep firing in rapid bursts.⁴⁵

More recent research has added some nuance to this picture. One study found that the effect may involve slow binding to fast-inactivated channel states rather than selective binding to slow-inactivated states per se, a subtle but meaningful distinction for neuroscientists trying to design better drugs.⁶ For patients, the practical takeaway is the same: lacosamide calms down hyperexcitable neurons through a mechanism that older drugs do not use, which is why it can work for people who have not responded to other treatments.

This unusual mechanism also explains part of the CNS side-effect profile. Any drug that modulates sodium channels in the brain can produce dizziness, sedation, or a vaguely “altered” feeling at high enough doses. Those effects overlap with the subjective experiences that recreational drug users might rate as mildly pleasant on a research questionnaire, even if the same effects would just feel like unwanted side effects to someone taking the drug for seizures.

What Poison Center Data Shows About Real-World Misuse

If lacosamide had serious abuse potential, you would expect to see patterns in poison center reports: intentional misuse, people taking large amounts to get high, recreational exposures climbing over time. A nine-year analysis of lacosamide exposures reported to U.S. poison centers tells a different story. Of 1,125 exposures reported, the majority were therapeutic errors (about 56%), meaning someone accidentally took a double dose or mixed up medications. Suicide attempts accounted for roughly 15% of cases.⁷

What the data did not show was a meaningful wave of recreational misuse. Poison center surveillance is an imperfect tool, since not every case of drug misuse ends up in a call to a poison center. But when a drug becomes popular for recreational use, the signal usually shows up in this kind of tracking system. The absence of that signal for lacosamide suggests that whatever detectable effects the clinical study picked up at 800 mg have not translated into a street-level demand for the drug.

How Scheduling Affects People Who Need the Drug

Schedule V is the gentlest scheduling tier, but it still imposes real barriers. Because lacosamide is a controlled substance, prescriptions may require biometric data or a physical signature. “Refill too soon” policies can block patients from filling a prescription even a day early. Mail-order availability may be restricted depending on state law. And pharmacies that do not carry much controlled-substance inventory may not keep lacosamide reliably in stock.

These are not hypothetical problems. A survey of neurologists found that 99% reported having patients experience delayed refills of antiseizure medications due to controlled-substance restrictions. Even more striking, 96% of surveyed neurologists reported that patients had experienced breakthrough seizures because of scheduling-related prescription delays.⁸ For a drug like lacosamide, where the actual misuse signal is low, this tradeoff looks increasingly hard to justify. Breakthrough seizures are not minor inconveniences. They can result in injuries, hospitalizations, loss of driving privileges, and in some cases death.

The survey’s authors noted that controlled-substance restrictions create practical barriers to reliably obtaining scheduled antiseizure prescriptions and can increase the risk of morbidity and mortality.⁸ This has prompted growing discussion among epilepsy specialists about whether the scheduling of lacosamide, and other low-risk antiseizure medications like it, is doing more harm than good.

Other Antiseizure Drugs in the Same Boat

Lacosamide is not the only newer antiseizure medication to receive a controlled-substance designation. Drugs like perampanel, eslicarbazepine, and brivaracetam have all been subject to formal human abuse-potential studies as part of their regulatory review.² Of these, perampanel ended up in Schedule III, a higher category than lacosamide, reflecting a stronger abuse signal in its human studies. Eslicarbazepine was not ultimately scheduled, and brivaracetam landed in Schedule V alongside lacosamide.

The trend toward evaluating and scheduling newer antiseizure medications reflects a broader shift in how the FDA and DEA approach drugs that affect the central nervous system. Older antiseizure drugs like carbamazepine and phenytoin were never formally scheduled, partly because they were approved in an era when the abuse-potential assessment framework was less structured. Whether they would be scheduled today if subjected to the same modern evaluation is an open question, since virtually any drug that modulates brain activity will produce some detectable subjective effects at supratherapeutic doses.

Pharmacokinetics and Why High Doses Are Unlikely to Be Chased

Lacosamide is rapidly absorbed when taken by mouth, with peak blood levels reached within about half an hour to four hours. Its oral bioavailability is essentially complete at doses up to 800 mg, meaning the body absorbs nearly all of what is swallowed.⁹ On paper, that high bioavailability might look like a risk factor: people do not need to inject or snort the drug to get its full effect. But the absorption profile also means there is no “rush” associated with oral intake, just a gradual rise in blood levels over a few hours.

The same pharmacokinetic study noted that lacosamide has a relatively long half-life and low protein binding, properties that make it a good seizure drug but a poor recreational one. People seeking a high generally want rapid onset, intense peak effects, and a quick return to baseline. Lacosamide delivers none of those things. Add in the nausea and dysphoria that showed up at 800 mg in the abuse-potential study, and the drug’s profile does not match what people typically look for when misusing medications.

Lacosamide Beyond Epilepsy

One area where the controlled-substance designation creates friction is off-label prescribing for pain. Because lacosamide works on sodium channels, and sodium channels play a central role in how pain signals travel along nerves, researchers and clinicians have explored its use in neuropathic pain conditions. In one published case, a patient with a painful neuropathy saw pain ratings drop dramatically during lacosamide treatment, and nerve fiber recordings confirmed reduced spontaneous activity in pain-sensing fibers.¹⁰ A broader expert review by the Spanish Pain Society listed lacosamide among drugs that could benefit neuropathic pain patients if studied further.¹¹

For pain specialists, the controlled-substance label adds another layer of hesitation. Prescribing a Schedule V drug off-label for pain puts a doctor in a position of extra scrutiny, particularly at a time when regulators are sensitive to controlled substances being used outside their approved indications. This does not mean the practice is illegal or inappropriate, but it does mean some clinicians may avoid recommending lacosamide for pain even when the pharmacology makes sense for a particular patient.

The Rescheduling Debate

There is a growing sense among epilepsy specialists that the Schedule V designation for lacosamide may warrant reconsideration. The original scheduling was based on a single clinical study showing mild positive effects at a dose four times higher than what patients actually take, effects that came with pronounced nausea and dysphoria. Nine years of poison center data show no significant recreational misuse pattern. And the downstream consequences for patients, including nearly universal reports of delayed refills and widespread breakthrough seizures, are well documented.

Rescheduling a drug under the Controlled Substances Act is not simple. It requires a formal petition, a review by the DEA and the Department of Health and Human Services, and public comment. The process can take years. But the conversation is happening, driven partly by the survey data showing that almost every neurologist in the country has seen patients harmed by the restrictions.⁸ Whether that conversation leads to actual policy change remains to be seen, but the clinical case for revisiting lacosamide’s scheduling has only gotten stronger over time.

State-Level Variation in Controlled-Substance Rules

Federal scheduling sets the floor, but individual states can impose additional restrictions on controlled substances. Some states require electronic prescribing for all controlled substances, including Schedule V drugs. Others have prescription drug monitoring programs that flag patients filling controlled-substance prescriptions at multiple pharmacies. A handful of states treat Schedule V drugs nearly the same as higher-schedule medications when it comes to pharmacy dispensing requirements.

For someone taking lacosamide, this patchwork means that the difficulty of getting your prescription filled can vary substantially depending on where you live. Moving to a new state, switching pharmacies, or traveling with your medication can all introduce unexpected friction. If you are on lacosamide and planning a relocation or extended trip, it is worth checking the controlled-substance dispensing rules in your destination state ahead of time. Some patients keep a letter from their neurologist explaining the medical necessity, though this is not a formal legal requirement.